SOPHiA GENETICS (SOPH) Stock Price, News & Analysis

Company Overview

SOPHiA GENETICS Ltd. is a healthcare technology company that develops data-driven medicine solutions for healthcare institutions, pharmaceutical companies and research organizations. The company’s platform is designed to help users analyze complex genomic and multimodal data and apply insights to clinical research and patient care.

Its core offering, the SOPHiA DDM platform, combines cloud-based software, artificial intelligence and machine-learning tools to support the interpretation of genomic data. The platform is used in areas including oncology, hereditary diseases and other clinical applications, helping laboratories manage workflows, identify relevant genetic variants and generate clinically actionable information.

Founded in 2011 and headquartered in Rolle, Switzerland, SOPHiA GENETICS serves a global network of healthcare and life sciences organizations. The company operates internationally through collaborations with hospitals, laboratories, pharmaceutical companies and research institutions. It became a publicly traded company on the Nasdaq in 2021.

Key Stats

• Today's Range: $7.91 to $8.50
• 50-Day Range: $5.55 to $8.92
• 52-Week Range: $3.75 to $8.98
• Volume: 700,747 shs
• Average Volume: 620,598 shs
• Market Capitalization: $673.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Hold

SOPHiA GENETICS Stock Analysis - MarketRank™

SOPHiA GENETICS scored higher than 75% of companies evaluated by MarketBeat, and ranked 190th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

SOPHiA GENETICS has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

SOPHiA GENETICS has a consensus price target of $10.00, representing about 24.5% upside from its current price of $8.03.

Amount of Analyst Coverage

SOPHiA GENETICS has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SOPHiA GENETICS are expected to grow in the coming year, from ($0.77) to ($0.31) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SOPHiA GENETICS is -6.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SOPHiA GENETICS is -6.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SOPHiA GENETICS has a P/B Ratio of 11.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.34% of the float of SOPHiA GENETICS has been sold short.

Short Interest Ratio / Days to Cover

SOPHiA GENETICS has a short interest ratio ("days to cover") of 1.67, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SOPHiA GENETICS has recently decreased by 3.05%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SOPHiA GENETICS does not currently pay a dividend.

Dividend Growth

SOPHiA GENETICS does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

SOPHiA GENETICS has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

MarketBeat Follows

2 people have added SOPHiA GENETICS to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, SOPHiA GENETICS insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,957,300.00 in company stock.

Percentage Held by Insiders

4.88% of the stock of SOPHiA GENETICS is held by insiders.

Percentage Held by Institutions

31.59% of the stock of SOPHiA GENETICS is held by institutions.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Technology
• Sub-Industry: Healthcare Technology
• Current Symbol: NASDAQ:SOPH
• CIK: 1840706
• Web: www.sophiagenetics.com
• Phone: 41-21-694-1060
• Fax: N/A
• Employees: 415
• Year Founded: 2011

Price Target and Rating

• Average Price Target for SOPHiA GENETICS: $10.00
• High Price Target: $14.00
• Low Price Target: $7.00
• Potential Upside/Downside: +24.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$79 million
• Net Margins: -93.86%
• Pretax Margin: -93.19%
• Return on Equity: -132.47%
• Return on Assets: -45.97%

Debt

• Debt-to-Equity Ratio: 0.58
• Current Ratio: 2.69
• Quick Ratio: 2.55

Sales & Book Value

• Annual Sales: $77.27 million
• Price / Sales: 8.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 11.64

Miscellaneous

• Outstanding Shares: 83,890,000
• Free Float: 79,801,000
• Market Cap: $673.64 million
• Optionable: Not Optionable
• Beta: 0.95